SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors upcoming FDA decision on deramiocel for Duchenne muscular dystrophy is driving attention, with traders focused on the November 22 target date and the companys amended application emphasizing upper-limb function data. Bullish traders interpret the longer-term data, rare-disease policy discussions and recent commercial hiring as encouraging signs, while skeptics cite prior FDA concerns and say approval remains uncertain.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX is drawing attention for its breakout ahead of the expected Q3 earnings report, with traders focused on BRIUMVIs growth and possible further upside. Buyout and short-squeeze chatter is prominent but speculative; some traders instead attribute the move to earnings expectations and the companys commercial momentum.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCath reimbursement could fall after early 2027 has fueled a sharp selloff and concern about future pricing and revenue. Traders disagree over whether the warning signals sustained pressure or is only a preliminary estimate, pointing to CMSs more stable outlook while criticizing CorMedixs lack of clarification.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is drawing attention after a sharp Nasdaq selloff tied to weakness in technology and semiconductor stocks, with traders debating whether concerns about AI spending and earnings justify more downside or whether the decline is an oversold dip to buy. The late-session rebound prompted some dip-buying optimism, but bearish traders continued to warn that the correction may not be over.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS REGAL Phase 3 leukemia trial reached its prespecified event threshold, triggering final analysis and putting the GPS survival readout in focus. Traders are sharply divided over whether GPS will show a benefit or whether control-arm outcomes and trial assumptions could undermine the bull case, amid volatile trading and speculation about short positioning.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Precigens PAPZIMEOS commercial launch and stronger-than-expected quarterly results, including a move to profitability, are driving bullish discussion about its growth prospects. Traders also debate whether potential INO-3107 competition could challenge PAPZIMEOS and whether heavy short interest is amplifying the stocks moves.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,105,365. The last known price of Bitcoin is 76,874.98691422 USD and is down -4.82 over the last 24 hours. It is currently trading on 12773 active market(s) with $58,826,736,014.03 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

A reported major Binance security breach and temporary withdrawal suspension have fueled Bitcoin selling and concerns about crypto exchange security. Traders disagree over whether the incident signals broader risk or is isolated to Binance, with some viewing the pullback as a buying opportunity and others warning of further downside.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

ARM is caught in a sharp semiconductor and AI-stock selloff, with traders citing its rich valuation and questioning whether AI demand can support the growth priced in. Some see the drop as an overdone sector-driven correction and are buying the dip, while others expect further downside.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovins steep selloff ahead of its quarterly report is fueling concern about slowing ad growth, analyst target cuts, and weakness across advertising-related stocks. Traders debate whether the decline reflects deteriorating prospects or has overshot the companys growth and cash-generation fundamentals, with earnings seen as a key test.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

Silvers sharp selloff, amid inflation concerns and expectations of higher interest rates, is driving attention to SLV. Traders are split between calling the decline an oversold buying opportunity and warning that selling may continue, with some blaming market manipulation without evidence.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

12 Health Care Stocks Moving In Tuesday's After-Market Session

Gainers

XORTX Therapeutics (NASDAQ:XRTX) shares moved upwards by 19.3% to $1.14 during Tuesday's after-market session. The company's market cap stands at $1.8 million.
Edesa Biotech (NASDAQ:EDSA) shares roseread more...

Edesa Biotech Stock Sinks After Fresh Capital Raise

Edesa Biotech Stock falls in premarket trading as investors weigh a $25 million offering, new warrants and potential dilution.read more...

EDSA Stock Soars More Than 700% So Far This Year: Wall Street Eyes Further Upside In Run Up To Acute Kidney Injury Data Reveal

Equity

According to data from Koyfin, the sole analyst covering EDSA rates it a ‘Buy’ with a $14 price target.


Edesa Biotech (EDSA) to Release Earnings on Tuesday

Edesa Biotech (NASDAQ:EDSA) will be releasing earnings before the market opens on Tuesday, May 12. (View Earnings Report at...

Short Interest in Edesa Biotech, Inc. (NASDAQ:EDSA) Decreases By 32.5%

Edesa Biotech, Inc. (NASDAQ:EDSA - Get Free Report) saw a large decline in short interest in April. As of April 15th, there was short interest totaling 267,664 shares, a decline of 32.5% from the...

EDSA Stock Rallied Over 50% Today: What’s Ahead For The Small-Cap Biotech?

The rally comes ahead of the company CEO’s upcoming presentation at the ATS 2026 Respiratory Innovation Summit (RIS) and other pipeline catalysts.

Edesa Biotech (NASDAQ:EDSA) Rating Increased to Hold at Wall Street Zen

Wall Street Zen raised Edesa Biotech from a "sell" rating to a "hold" rating in a research note on Sunday...

Short Interest in Edesa Biotech, Inc. (NASDAQ:EDSA) Expands By 9,253.7%

Edesa Biotech, Inc. (NASDAQ:EDSA - Get Free Report) saw a significant increase in short interest during the month of February. As of February 27th, there was short interest totaling 1,411,103 shares...

Best Biotech Stocks To Follow Today - March 7th

Danaher, Moderna, Vertex Pharmaceuticals, argenex, Iovance Biotherapeutics, Edesa Biotech, and ImmunityBio are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool...

Pardeep Nijhawan Purchases 10,000 Shares of Edesa Biotech (NASDAQ:EDSA) Stock

Edesa Biotech, Inc. (NASDAQ:EDSA - Get Free Report) CEO Pardeep Nijhawan purchased 10,000 shares of Edesa Biotech stock in a transaction dated Thursday, March 5th. The shares were purchased at an...

Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquisition, development, and commercialization of drug candidates for medical dermatology and respiratory diseases. Its clinical studies include EB05 for Acute Respiratory Distress Syndrome (ARDS), EB07 for systemic sclerosis (SSc), EB01 for chronic Allergic Contact Dermatitis (ACD), and EB06 for vitiligo. The company was founded by Pardeep Nijhawan on June 12, 2007 and is headquartered in Markham, Canada.

Edesa Biotech Inc

Bearish Sentiment

<ul class="summary-bullets"><li>Edesa said it will deliver an oral presentation at the 63rd European Renal Association (ERA) Congress, scheduled for June 3–6 in Glasgow, Scotland.</li><li>At the upcoming conference, Edesa will present data drawn from its late-stage study in patients with respiratory distress who also developed acute kidney injury.</li><li>The Toronto-based clinical-stage biopharmaceutical company, which remains pre-revenue, ended its March quarter with $10.0 million in cash and cash equivalents and $8.2 million in working capital.</li></ul> Edesa Biotech (EDSA) shares rallied as much as 34% on Tuesday, snapping a three-day streak of closing in the red, after the clinical-stage company announced it will present new exploratory data on its lead candidate, paridiprubart, for acute kidney injury at a major European nephrology conference.Edesa said it will deliver an oral presentation at the 63rd European Renal Association (ERA) Congress, scheduled for June 3–6 in Glasgow, Scotland. The talk is set for June 5 at 4:30 p.m. local time.<a href="https://stocktwits.com/symbol/EDSA">EDSA stock</a> has gained 506% over the past 12 months. However, according to data from Koyfin, the sole analyst covering EDSA rates it a ‘Buy’ with a $14 price target, representing a further potential upside of 56% from the last closing price.<h2 class="st-heading-2">Upcoming Presentation</h2>At the upcoming conference, Edesa will present data drawn from its late-stage study in patients with respiratory distress who also developed acute kidney injury, a common, high-mortality complication. Acute kidney injury affects an estimated 13 million people worldwide each year and currently has no approved targeted pharmacological therapies.“The ERA Congress represents a critical platform to advance awareness of paridiprubart’s potential in AKI—a disease with profound unmet need and limited therapeutic options,” said Par Nijhawan, CEO of Edesa Biotech. “Our Phase 3 data demonstrate a consistent, statistically significant reduction in mortality in AKI patients, grounded in a well-established mechanism.”<h2 class="st-heading-2">EDSA’s Financials</h2>Last week, Edesa reported fiscal second-quarter 2026 results for the period ended March 31, posting a net loss of $4.2 million, or $0.49 per share, compared with a $1.6 million loss, or $0.30 per share, in the year-ago quarter. Total operating expenses rose sharply to $4.3 million from $1.6 million, driven largely by a $2.3 million increase in research and development spending tied to manufacturing and clinical preparations for its EB06 vitiligo program and regulatory and manufacturing readiness activities for paridiprubart. The Toronto-based clinical-stage biopharmaceutical company, which remains pre-revenue, ended the quarter with $10.0 million in cash and cash equivalents and $8.2 million in working capital.<h2 class="st-heading-2">What Do Retail Traders Think About EDSA?</h2>On Stocktwits, retail sentiment around EDSA stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.A Stocktwits user highlighted the potential of paridiprubart as a solution for respiratory issues in serious COVID cases.<stembedurl>https://www.stocktwits.com/stockzorg/message/653815232</stembedurl>Another user, however, dismissed the rally as based on a “vague promise” of data in a few weeks.<stembedurl>https://www.stocktwits.com/vanderuk/message/653811537</stembedurl> &nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-shares-edge-lower-as-giant-houston-solar-factory-plans-emerge/cZXuvFEReNQ">Tesla Shares Edge Lower As Giant Houston Solar Factory Plans Emerge</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

According to data from Koyfin, the sole analyst covering EDSA rates it a ‘Buy’ with a $14 price target.

Vanguard Extended Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$2.57
Prev Close	$2.70
Open	$2.86
Dividend Yield	0.00%
50-Day Moving Average	$3.82
Beta	0.49
Avg. Volume	38,672.84
PE Ratio	-1.60

52-Week High	$20.32
52-Week Low	$0.72
Market Capitalization	$36.48M
EPS (Annual)	-$1.27
Price to Book	65.19
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

EDSA Fundamentals